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kaisa.ivaska@utu.fiAbstractInsulin signaling in bone-forming osteoblasts stimulates bone formation and promotes the
release of osteocalcin (OC) in mice. Only a few studies have assessed the direct effect of
insulin on bone metabolism in humans. Here, we studied markers of bone metabolism in
response to acute hyperinsulinemia in men and women. Thirty-three subjects from three
separate cohorts (nZ8, nZ12 and nZ13) participated in a euglycaemic hyperinsulinemic
clamp study. Blood samples were collected before and at the end of infusions to determine
the markers of bone formation (PINP, total OC, uncarboxylated form of OC (ucOC)) and
resorption (CTX, TRAcP5b). During 4 h insulin infusion (40 mU/m2 per min, low insulin), CTX
level decreased by 11% (P!0.05). High insulin infusion rate (72 mU/m2 per min) for 4 h
resulted in more pronounced decrease (K32%, P!0.01) whereas shorter insulin exposure
(40 mU/m2 per min for 2 h) had no effect (PZ0.61). Markers of osteoblast activity remained
unchanged during 4 h insulin, but the ratio of uncarboxylated-to-total OC decreased in
response to insulin (P!0.05 and P!0.01 for low and high insulin for 4 h respectively). During
2 h low insulin infusion, both total OC and ucOC decreased significantly (P!0.01 for both).
In conclusion, insulin decreases bone resorption and circulating levels of total OC and ucOC.
Insulin has direct effects on bone metabolism in humans and changes in the circulating levels
of bone markers can be seen within a few hours after administration of insulin.Key Words
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onEndocrine Connections
(2015) 4, 155–162IntroductionBone is increasingly recognized as an effector in energy
metabolism via its interactions with other tissues (1, 2).
The role of bone-derived osteocalcin (OC) as a novel
endocrine regulator of glucose and lipid metabolism was
originally identified in mice, in which OC was shown toact as a hormone to increase proliferation of pancreatic
b cells, insulin secretion and insulin sensitivity (3, 4).
Osteocalcin is specifically expressed in osteoblasts and
osteocytes, and it is secreted into the circulation during
bone formation (5). The structure of OC is characterized bysed under a Creative Commons
Commercial 4.0 International License.
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protein high affinity to hydroxyapatite (HA) in bone
matrix (6). Only the uncarboxylated form of OC (ucOC)
appears to induce the expression of insulin and adipo-
nectin in b cells and adipocytes (4), putatively via the
activation of GPRC6A (7, 8).
Bone is a potential target for insulin, which may exert
positive effects on bone density and strength (9, 10).
Clinical observations in patients with types 1 and 2
diabetes mellitus suggest that insulin may act as an
anabolic agent in bone and preserve bone mass in humans
(11, 12). Insulin receptors have been detected in osteo-
sarcoma cell lines and rodent osteoblasts (10, 13, 14, 15),
osteoclast-like cells (16) and in primary human osteoblasts
differentiated from bone marrow-derived mesenchymal
stem cells (17). In vitro, insulin signaling promotes
osteoblast differentiation and OC expression in mouse
calvarial osteoblasts (18). The role of insulin receptor
signaling in vivo was demonstrated by deleting insulin
receptors specifically in the mouse osteoblasts (19, 20).
Insulin signaling in osteoblasts stimulated bone formation
and increased peak bone mass during development (19).
In addition, the studies suggested that insulin down-
regulates the expression of osteoprotegerin, thereby
indirectly up-regulating bone resorption and the release
of matrix-bound OC, particularly in its uncarboxylated
form (20). These data proposed a two-directional regulat-
ory pathway, where bone protein (OC) regulates b-cells
and insulin release, while insulin participates in the
release of OC from the skeleton (21). Whether a similar
regulatory system is present in humans is controversial
(22, 23). Several studies in humans have reported a
relationship between OC and various measures of glucoseTable 1 Characteristics of the three cohorts analyzed using eugly
clamped at 5 mmol/l in all experimental cohorts.
Cohort 1
Median
Insulin infusion rate (mU/m2 per min) 40
Clamp duration (min) 240
Gender (F/M) 3/5
Age (years) 54.4
Height (cm) 171.6
Weight (kg) 96.9 7
BMI (kg/m2) 32.7
Waist-to-hip ratio 0.99
Fasting plasma glucose (mmol/l) 5.4
Fasting serum insulin (mU/l) 10.0
Serum insulin at the end of insulin infusion (mU/l) 63.0
Whole body glucose uptake (mol/kg per min) 30.5
http://www.endocrineconnections.org
DOI: 10.1530/EC-15-0022
 2015 The authors
Published by Bioscientifica Ltdmetabolism, but the results have been inconsistent and
mostly assessed total OC levels (22, 23, 24, 25, 26, 27). The
discrepancies between different study designs, popu-
lations, and comorbidities create uncertainty when
evaluating the role of OC in glucose metabolism in
human physiology. Studies are further complicated by
the difficulties in accurately measuring circulating levels
on ucOC and the controversy regarding the optimal assay
design for ucOC (28). It is also unclear whether changes in
osteoblast function and bone metabolism can be observed
in response to hyperinsulinemia in humans in vivo.
Here, we employed the euglycemic hyperinsulinemic
clamp technique (29) to study whether insulin affects
markers of bone remodeling, particularly OC, in humans.
A few studies have applied this technique to assess acute
insulin-driven changes in bone metabolism (30, 31, 32)
with the focus on physiological variations in circulating
levels of insulin. We analyzed in parallel three cohorts,
in which insulin infusion rate (40 or 72 mU/m2 per min)
and duration of the clamp (2 or 4 h) varied to achieve
physiological or supraphysiological insulin concentrations
in the presence of normoglycemia. This experimental
set-up should isolate the direct effects of insulin on bone.Subjects and methods
Study subjects
Three separate cohorts were recruited (Table 1). Eight
healthy volunteers without any chronic diseases or regular
medications participated in cohort 1 (five men and three
women) with median age of 54.4 years and BMI of
32.7 kg/m2 (33). Cohort 2 consisted of 12 healthy youngcaemic hyperinsulinemic clamp technique. Plasma glucose was
(nZ8) Cohort 2 (nZ12) Cohort 3 (nZ13)
Range Median Range Median Range
– 72 – 40 –
– 240 – 120 –
– 0/12 – 13/0 –
37–63 23.5 18–34 73.7 69–79
168–177 179.2 173–190 161.8 150–168
1.7–108.2 68.3 63.6–91.0 64.9 55.3–100.7
24.5–34.5 21.4 18.3–28.7 26.1 19.8–37.4
0.86–1.07 0.86 0.76–0.91 0.89 0.79–0.96
4.7–6.6 5.4 4.9–5.9 5.8 5.3–6.4
4–16 3.0 2–6 8.0 3–19
34–75 105.0 69–114 76.0 51–99
11.9–46.5 54.7 46.3–81.5 26.7 8.7–53.3
This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
E
n
d
o
cr
in
e
C
o
n
n
e
ct
io
n
s
Research K K Ivaska et al. Acute hyperinsulinemia and
bone
3–8 4 :157men with median age of 23.5 years and BMI of 21.4 kg/m2
(34). Cohort 3 consisted of 13 healthy elderly women
(median age 73.7 years) with median BMI of 26.1 kg/m2.
All subjects were normoglycemic.Study design
All cohorts were studied after an overnight fast using
euglycaemic hyperinsulinemic clamp. Cohort 1 had a
hyperinsulinemic (40 mU/m2 per min, termed ‘low
insulin’ hereinafter) euglycemic (5 mmol/l) clamp for
4 h. Cohort 2 also had a 4-h euglycemic clamp but with
supraphysiological insulin infusion rate (72 mU/m2 per
min, termed ’high insulin’ hereinafter). The elderly
women in cohort 3 had a shorter protocol of hyperinsu-
linemic (40 mU/m2 per min) euglycemic clamp for 2 h. All
studies were approved by the Ethical Committees of
Helsinki University Central Hospital (cohorts 1 and 2) or
Turku University Hospital (cohort 3) and a written
informed consent was given by all study participants.
The studies were carried out according to the principles of
Declaration of Helsinki.
The clamp study was initiated after an overnight fast
at 0900 h and blood samples were collected at the
beginning of the study before infusions (0 min) and at
the end of infusions (120 or 240 min, depending on the
experimental protocol, Fig. 1). Serum was stored in
aliquots at –70 8C until analysis and all samples were
analyzed in duplicate in a blinded fashion. Whole body
insulin sensitivity was calculated as glucose disposal rate
(GDR, orM value; mmol/kg permin) during the last hour of
the clamp (22).1
Cohort 1 (n=8)
Cohort 2 (n=12)
Cohort 3 (n=13)
0 ' 60 '
= sample for bone marker an
Time (min)
Hyperinsulinemic eug
Figure 1
Experimental design. Glucose was clamped at 5 mM and insulin infusion rates w
with triangles. Samples were analysed for PINP, CTX, TRAcP5b, TotalOC and uc
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Serum total OC (total OC) was determined with two-site
immunoassay using previously described protocols
(35, 36). Two-site immunoassay for total OC is based on
monoclonal antibodies (Mabs) 2H9 and 6F9 and detects
the N-terminal midsegment of the OC molecule (37). In
brief, 200 ng of biotinylated 2H9 and 100 ng of europium-
labelled 6F9 per well was used. Synthetic peptide of human
OC amino acids 1–49 (Advanced Chemtech, Louisville,
KY, USA) was used as a calibrator. Streptavidin-coated
microwell plates were from Kaivogen (Turku, Finland) and
other immunoassay reagents (Delfia Assay Buffer, Wash
Solution and Enhancement solution) from Perkin Elmer
Life Sciences (Turku, Finland). Time-resolved fluorescence
was measured with Victor2 Multilabel Counter (Perkin-
Elmer Life Sciences). Intra- and inter-assay variations for
the assay are reported to be!5 and!8% respectively (35).
ucOC was determined with in-house assay protocol based
on HA binding, as previously used in mouse studies (3).
The amount of OC bound to HA is dependent on
carboxylation status and the amount of HA used (38),
and we optimized the amount of HA best suitable for
serum samples. In the optimized assay protocol, 100 ml of
diluted sample was mixed with 1 mg HA slurry (Type I,
buffered aqueous suspension, Sigma) and incubated for
15 min on ice. Supernatant was collected by centri-
fugation (8000 g, 5 min) and OC content in the unbound
fraction (containing ucOC) was measured with the total
OC immunoassay procedure based on antibodies 2H9 and
6F9 previously described, allowing us to compare total OC
and ucOC values. Serum samples were diluted 1:1 prior to20 '
Ins 40 mU
Ins 72 mU
Ins 40 mU
240 '180 '
alysis
lycemic (5 mM) clamp
ere 40 or 72 mU/m2 per min. Timepoints for sample collection are indicated
OC.
This work is licensed under a Creative Commons
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validated with synthetic peptides of carboxylated human
OC (with g-carboxyglutamic acid at positions 17, 21 and
24, from Advanced Chemtech) and uncarboxylated
human OC (with glutamic acid at positions 17, 21 and
24, from Peptide 2.0, Chantilly, VA, USA).Serum CTX, TRAcP5b and PINP
Bone resorption and osteoclast activity was assessed by
measuring serum levels of C-terminal crosslinked telopep-
tides of type I collagen (CTX) and tartrate-resistant acid
phosphatase 5b (TRAcP5b) using serum IDS-iSYS CTX-I
(CrossLaps) ELISA and BoneTRAP (TRAcP 5b) ELISA (both
from IDS Ltd, Boldon, Tyne and Wear, UK). Bone
formation was assessed by measuring serum intact
N-terminal propeptide of type I collagen (PINP) using
IDS-iSYS Intact PINP assay (IDS Ltd, UK). According to the
manufacturer, intra- and inter-assay variations for the
assays are for bCTX-I!6 and!10%, for TRAcP5b!6 and
!6% and for PINP !4 and !6% respectively. Measure-
ments were performed by ValiRx Finland Plc (Oulu,
Finland). In addition, the plasma levels of 25-hydroxy
vitamin D (25(OH)D), the predominant circulating
metabolite of vitamin D, were measured with automated
electrochemiluminescence binding assay (Cobas 8000,
Roche Diagnostics) in cohort 3.Statistical analysis
The data are given as medians with range or interquartile
range. Bone markers were non-normally distributed
(Shapiro-Wilk’s test !0.95) and the statistical differences
between values before and after infusion were calculated
using Wilcoxon’s signed rank test. Spearman’s test was
used to study the correlations between variables. For
statistical analysis we used SPSS, version 22 (SPSS, Inc) and
the level of significance was set at P!0.05.Results
Glycemic control during studies
Low insulin infusion rate increased serum insulin levels
sixfold (PZ0.012) in cohort 1 and eightfold (PZ0.003) in
cohort 3. High insulin infusion rate (cohort 2) resulted in
a 30-fold increase in serum insulin (PZ0.003) and 67%
higher insulin level during clamp as compared to cohorts 1
and 2. Plasma glucose levels remained at 5 mmol/l during
insulin infusions in all cohorts (data not shown). Wholehttp://www.endocrineconnections.org
DOI: 10.1530/EC-15-0022
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Published by Bioscientifica Ltdbody glucose uptake had variation in all cohorts. In cohort
1 (overweight men and women), the median GDR value
was 30.5 mmol/kg per min (range 11.9–46.5). The median
GDR value in cohort 2 (young men with normal body-
weight) was 54.7 mmol/kg per min (range 46.3–81.5) and
in cohort 3 (elderly women), the median GDR was
26.7 mmol/kg per min (range 8.7–53.3). In cohort 3, the
median plasma level of 25(OH)D was 75.2 nmol/l, and
only two subjects (15%) had insufficient levels of
circulating 25(OH)D (i.e. below 50 nmol/l by the Finnish
National Guidelines).Bone resorption in response to euglycemic
hyperinsulinemia
After 4 h insulin infusion, there was a small but significant
decrease in bone resorption marker CTX (median K11%,
PZ0.035, Fig. 2A). High-dose insulin exposure resulted
in a similar, but more pronounced suppression of bone
resorption measured by CTX (median K32%, PZ0.008,
Fig. 2B). In contrast, shorter 2 h insulin infusion did not
alter serum CTX (medianC1.0%, PZ0.61. Fig. 2C). Levels
of osteoclast-derived TRAcP5b, a marker of osteoclast
number, varied and no consistent pattern in response to
insulin were observed. A small, but significant decrease of
4.6% (PZ0.01) was observed in 2 h insulin exposure and
a decreasing trend was observed also after the longer 4 h
exposure (medianK13%, PZ0.05). However, no decrease
was detected in TRAcP5b in cohort 2 (PZ0.27). The
changes in bone markers in response to insulin infusion
are summarized in Fig. 2 and Supplementary Figure 1,
see section on supplementary data given at the end of
this article.Bone formation in response to euglycemic
hyperinsulinemia
PINP, a marker of bone formation, remained unchanged
during both high and low as well as long and short insulin
infusions (PO0.05 for all). The circulating levels of total
OC remained unchanged in response to insulin in 4 h
hyperinsulinemic clamps (PO0.05 in both cohorts). In
contrast, the level of ucOC was reduced by a median of
27% in response to high insulin infusion rate (PZ0.010,
Fig. 2B) and a similar, although not significant, decrease
was observed with low insulin infusion rate (median
K25%, PZ0.069, Fig. 2A). The ratio of uncarboxylated-
to-total OC was decreased in response to insulin exposure
both with low (PZ0.012) and high (PZ0.005) insulin
infusion. Shorter 2-h insulin exposure resulted in decreaseThis work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
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Figure 2
%-changes in bone markers in response to A) 4 h euglycemic hyper-
insulinemic (40 mU/m2 per min) clamp (cohort 1), B) 4 h euglycemic
hyperinsulinemic clamp with high (72 mU/m2 per min) insulin infusion rate
(cohort 2) or C) 2 h euglycemic hyperinsulinemic (40 mU/m2 per min) clamp
(cohort 3). Results are shown as %-change from the baseline (0’) value. The
lines inside the boxes represent the 50th percentile; the limits of the boxes
represent the 25th and 75th percentiles, and the whiskers the 10th and
90th percentiles. Individual samples are shown with crosses and the mean
value with a square. P values for the changes (from baseline to the
endpoint, Wilcoxon signed ranks test) are shown below the x-axis
(**P!0.01 and *P!0.05).
E
n
d
o
cr
in
e
C
o
n
n
e
ct
io
n
s
Research K K Ivaska et al. Acute hyperinsulinemia and
bone
5–8 4 :159
http://www.endocrineconnections.org
DOI: 10.1530/EC-15-0022
 2015 The authors
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PZ0.009, Fig. 2C). The ratio of uncarboxylated-to-total
OC varied and was not significantly altered (PZ0.53). We
also performed all analyses by excluding the two obese
individuals (BMI O30) in the 2 h insulin exposure
experiment. The main findings were the same after the
exclusions, with a decrease of 22% in totalOC (PZ0.005)
and 38% in ucOC (PZ0.019) and no change in
uncarboxylated-to-total OC ratio (PZ0.51).Associations between bone markers and
insulin sensitivity
We also explored the association between GDR, a measure
of insulin sensitivity, and baseline levels of bone markers.
Insulin sensitivity was positively associated with baseline
bone resorption measured by CTX (rZ0.91, PZ0.002) in
cohort 1. Correlations with other bone markers were not
significant, although a similar trend of positive association
was seen for PINP (rZ0.62, PZ0.102), total OC (rZ0.67,
PZ0.071), and ucOC (0.62, PZ0.102). Insulin sensitivity
of elderly women in cohort 3 also tended to associate with
several bone markers, although the associations were not
statistically significant (CTX rZ0.48, PZ0.12; PINP rZ
0.48, PZ0.12; total OC rZ0.37, PZ0.22; ucOC rZ0.44,
PZ0.14). In cohort 2 consisting of young individuals with
low BMI and high baseline bone turnover, no associations
between insulin sensitivity and baseline bone markers
were found (data not shown). This may be due to their
higher insulin sensitivity but it is also possible that the
relationship between insulin and bone metabolism
depends on physical condition, age and/or gender (39).Discussion
Our data indicate that acute pharmacological changes in
circulating insulin levels have immediate effects on bone
metabolism in humans. Insulin suppresses bone resorp-
tion (CTX) and decreases the levels of total OC and ucOC
in dose- and time-dependent manner.
Bone resorption marker was decreased while no
change was seen in bone formation markers 4 h after
insulin exposure. This suggests that insulin may act as an
anabolic agent for bone metabolism, by shifting the
balance in the favor of bone formation. However, no
direct effect of insulin on osteoblasts can be confirmed on
the basis of the current study, since we observed no change
in the circulating levels of PINP or total OC after 4 h. This
is in conflict with the mouse studies reporting increased
bone formation and OC secretion upon activation ofThis work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
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tion marker CTX was decreased in response to 4 h insulin
infusion, opposite of increased bone resorption predicted
by the mouse models. By measuring bone markers 2 or 4 h
after insulin exposure we were thus unable to confirm the
direct stimulatory effect of insulin on bone observed in
mice. Species-specific differences in OC between mice and
humans, such as the differences in the regulatory elements
of OC gene and the relatively low sequence conservation,
may complicate the extrapolation of the findings of mouse
models to humans (22, 23, 40).
Significant suppression in bone metabolism is
observed after ingestion of glucose and the effect of
postprandial insulin release on bonemetabolism is usually
of greatermagnitude than the effects observed in our study
(36, 41). Part of the postprandial effectmay bemediated by
insulin but also by the incretins, such as GIP (42) or GLP-2
(43), or even glucose itself may directly affect the bone
cells (44). The objective of our study was to test the effects
of insulin on bone metabolism with a steady glucose level.
The suppression of bone metabolism observed after
hyperinsulinemic euglycemic clamp suggests that insulin
also has direct effects in the bone microenvironment. The
differential responses in CTX and OC after 2 and 4 h
insulin infusion suggest that bone markers and total and
uncarboxylated forms of OC have different kinetics in
response to insulin. We cannot, however, exclude that
insulin also regulates other aspects of bone metabolism
over a different time period, or that the skeletal effects may
be different in acute and chronic metabolic challenge
in humans.
Small clamp studies isolating the effect of insulin on
bonemarkers have suggested that acute changes in insulin
levels donot regulate bonemetabolism inhumans (30, 31).
Basu et al. (31) used a 2–3 h stepped insulin infusions
accompanied by hyperglycemic (9.3 mmol/l) clamp and
failed to observe changes in bone markers, including CTX
and uncarboxylated OC. We used high insulin infusion,
longer exposure time and glucose was clamped at normal
physiological concentration (5 mmol/l). Longer exposure
to higher insulin may have uncovered some effects which
were not observed previously. Clowes et al. (30) used a 2 h
hyperinsulinemic euglycemic clamp with high insulin
infusion rate (80 mU/m2 per min) and reported no
significant change in bone formation and resorption
markers, which is in line with our 2 h hyperinsulinemic
euglycemic clamp, except for OC. In our study, the
association between insulin sensitivity and bone turnover
was weak, if any. Insulin sensitivity was positively,
although not significantly, associated to bone turnoverhttp://www.endocrineconnections.org
DOI: 10.1530/EC-15-0022
 2015 The authors
Published by Bioscientifica Ltdin two of the cohorts, but not in the cohort consisting of
young men with normal body weight. Levinger et al. (32)
observed a positive association between whole body
insulin sensitivity and OC in middle-aged obese men
and another study reported a borderline association
between total OC and insulin resistance which appeared
to be mediated by BMI (45). Based on these findings, the
proposed link between insulin sensitivity and bone
metabolism remains uncertain in humans and further
studies are required.
The strengths of our study include the use of two
different insulin infusion rates and durations. Our main
finding of a decrease in circulating CTX levels and to lesser
extent also uncarboxylated-to-total OC ratio by insulin is
corroborated by similar data from three independent
cohorts. The three different cohorts cannot, however, be
directly compared to each other due to differences in
baseline characteristics. We assessed the carboxylation of
OC with in-house HA binding method. The assay
performance was greatly dependent on the diluent and
the amount of HA, as reported (38), and a detailed
characterization of assays based on HA binding is
warranted. The limitations of our study include the
small number of subjects, due to the highly laborious
and invasive study protocol. Due to the small sample size,
it was not possible to statistically adjust for confounding
factors or to take into account the gender differences (39).
Differences in baseline characteristics of the cohorts, such
as age and BMI, may explain some of the differences
observed in the magnitude of responses. Further limi-
tation is the unavailability of PTHmeasurements. Previous
studies have reported a transient reduction in PTH in
response to insulin (30) and it remains to be evaluated
whether the decrease in PTHmediates the changes in bone
metabolism.
In summary, pharmacologically elevated insulin
levels decrease bone resorption and the levels of total
and ucOC within a few hours in euglycemic conditions.
Acute insulin exposure does not directly regulate bone
formation in humans, as assessed by the circulating
marker of bone formation (PINP).Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
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